biostudies-literatureUnknown9(5)Liu J<h4>Introduction</h4>The approximately 70% 12-month relapse in children experiencing the initial episode of steroid-sensitive nephrotic syndrome (SSNS) is a significant concern, with over 50% developing frequent relapses or steroid-dependent nephrotic syndrome (FRNS/SDNS). There is a lack of strategies to reduce relapse after the onset. Whether early administration of rituximab, which effectively reduces relapses in FRNS/SDNS, may be a solution has not been evaluated.<h4>Methods</h4>A prospective, multicenter, open-label, single-arm trial was conducted in China, with a 12-month follow-up. Children aged 1 to 18 years with the first episode of nephrotic syndrome (NS) were screened for eligibility. Proteinuria was evaluated daily using dipsticks. A dose of 375 mg/m² of rituximab waKidney international reports1220-1227https://www.ebi.ac.uk/biostudies/studies/S-EPMC11069012biostudies-literatureEarly Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome.PMC11069012Liu JShen QXie LQian BDeng FXu HZhang RYan WDou YZhang YSun SJiang XWang XLiu CZhang AfalseEarly Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome.<h4>Introduction</h4>The approximately 70% 12-month relapse in children experiencing the initial episode of steroid-sensitive nephrotic syndrome (SSNS) is a significant concern, with over 50% developing frequent relapses or steroid-dependent nephrotic syndrome (FRNS/SDNS). There is a lack of strategies to reduce relapse after the onset. Whether early administration of rituximab, which effectively reduces relapses in FRNS/SDNS, may be a solution has not been evaluated.<h4>Methods</h4>A prospective, multicenter, open-label, single-arm trial was conducted in China, with a 12-month follow-up. Children aged 1 to 18 years with the first episode of nephrotic syndrome (NS) were screened for eligibility. Proteinuria was evaluated daily using dipsticks. A dose of 375 mg/m² of rituximab wa2024-01-01T00:00:00Z2024 May2026-06-03T05:07:55.524Z2026-04-24T03:14:46.056ZS-EPMC110690123870781510.1016/j.ekir.2024.02.1395